Vestal Point Capital LP Boosts Holdings in Dianthus Therapeutics, Inc. $DNTH

Key Points

• Vestal Point Capital LP increased its stake in Dianthus Therapeutics by 58.1% in Q1, owning 1,700,069 shares worth approximately $30.84 million.
• Several analysts have given Dianthus Therapeutics a consensus rating of "Buy", with Target prices ranging from $34.00 to $54.00.
• Dianthus Therapeutics reported a Q2 EPS of ($0.88), missing expectations, and predicted a net loss with a negative return on equity of 34.72%.

Vestal Point Capital LP boosted its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 58.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,700,069 shares of the company's stock after purchasing an additional 625,069 shares during the period. Dianthus Therapeutics comprises 2.2% of Vestal Point Capital LP's holdings, making the stock its 16th biggest holding. Vestal Point Capital LP owned approximately 5.29% of Dianthus Therapeutics worth $30,839,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. US Bancorp DE grew its holdings in Dianthus Therapeutics by 2,013.3% during the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock valued at $29,000 after purchasing an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth approximately $59,000. GAMMA Investing LLC increased its position in shares of Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after acquiring an additional 3,758 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Dianthus Therapeutics by 21.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock worth $207,000 after acquiring an additional 1,647 shares during the period. Finally, Invesco Ltd. increased its position in shares of Dianthus Therapeutics by 7.4% during the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after acquiring an additional 790 shares during the period. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Stock Up 1.6%

Shares of NASDAQ DNTH traded up $0.40 during midday trading on Thursday, reaching $24.66. 348,965 shares of the company's stock traded hands, compared to its average volume of 335,391. The stock's 50 day simple moving average is $21.10 and its 200-day simple moving average is $20.06. Dianthus Therapeutics, Inc. has a one year low of $13.36 and a one year high of $32.27. The company has a market cap of $793.81 million, a price-to-earnings ratio of -7.59 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. The business had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. Equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently commented on DNTH. HC Wainwright reaffirmed a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Tuesday, May 13th. William Blair began coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They set an "outperform" rating on the stock. Wedbush raised their target price on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Finally, Robert W. Baird reduced their target price on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 13th. Seven equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $54.00.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.